

COMPUMEDICS LIMITED

(ACN 006 854 897)

ASX Half-year information – 31 December 2007

Lodged with the ASX under Listing Rule 4.2A.3

This information should be read in conjunction with the
30 June 2007 Annual Report.

Contents

Results for Announcement to the Market <i>(Appendix 4D item 2)</i>	2
Half-year report <i>(ASX Listing rule 4.2A1)</i>	4
Supplementary Appendix 4D Information <i>(Appendix 4D items 3 to 9)</i>	21

Compumedics Limited
Half-year ended 31 December 2007
(Previous corresponding period:
Half-year ended 31 December 2006)

Results for Announcement to the Market

				\$'000
Revenue from ordinary activities <i>(Appendix 4D item 2.1)</i>	Up/down	2%	to	20,076
Profit from ordinary activities after tax attributable to members <i>(Appendix 4D item 2.2)</i>	Up/down	250%	to	1,613
Net profit for the period attributable to members <i>(Appendix 4D item 2.3)</i>	Up/down	250%	to	1,613

Dividends/distributions <i>(Appendix 4D item 2.4)</i>	Amount per security	Franked amount per security
Final dividend (prior year)	n/a	n/a

Record date for determining entitlements to the dividend
(Appendix 4D item 2.5)

n/a

Explanation of Revenue *(Appendix 4D item 2.6)*

Revenues from continuing operations were 2% higher at \$20.1m for the half-year to 31 December 2007 compared to \$19.70m for the previous corresponding half-year. Whilst the underlying business continued to improve this was not reflected in the headline revenue numbers in Australian dollars due to:

- 1 the business not being able to ship all the orders it took through to 31 December 2007. The business took orders of about \$21m for the half-year to 31 December 2007, which compares to total orders taken in the corresponding half-year of \$19.6m or a 7% increase despite the exchange rate effect. The business was unable to ship all of these orders by 31 December 2007 in part because of the restrictive funding arrangements placed on the business by its now previous bankers; and
- 2 the on-going depreciation of the US dollar relative to the Australian dollar. The average AUD/USD exchange rate for the six months to 31 December 2007 was approximately 87 cents compared to 76 cents for the previous corresponding half-year. Had the Australian dollar stayed at the 76 US cent rate from the previous corresponding half-year reported revenues for the half-year to 31 December 2007 would have been closer to \$22m, some \$2m more than what has been reported.

Revenues from continuing operations in the global sleep business were static overall at \$8.6m for the half-year ended 31 December 2007 when compared to the previous corresponding half-year. This reflects strong sales growth out of all parts of the world offset by a weak US first half-year performance. The weaker sales in the US were not market related but business specific and steps have been taken to restore the business performance in the second half of the current financial year in the US sleep market.

The sales performance for the US business as a whole has also been affected by the much stronger Australian dollar to the US dollar as already stated.

Revenues from continuing operations in the Brain Research (Neuroscan) business were 24% ahead of the corresponding half-year at \$5.9m despite the exchange rate impact. This largely reflected the generation of new business in the half-year using existing products from both the Compumedics and Neuroscan businesses into brain function testing as part of clinical drug trials for pharmaceutical companies. The core Brain Research business in Asia and the US, not including this new pharmaceutical business, performed strongly whilst the Australian and European businesses declined compared to last year. The declines in these two geographic areas largely reflected the cyclical nature of grant funding for this business area.

Revenues from continuing operations for the DWL business were 23% less than for the previous corresponding half-year at \$2.7m compared to \$3.5m, reflecting lower sales in the US and Australia and some vendor specific issues in Germany with the delivery of new product. DWL had orders on hand that, had they shipped, would have seen the DWL business deliver growth for the half-year to 31 December 2007, compared to the previous corresponding half-year.

Explanation of Profit from ordinary activities after tax *(Appendix 4D item 2.6)*

Profit for the half-year to 31 December 2007 was \$1.6m compared to a profit of \$0.5m for the previous corresponding half-year.

The significant improvement in the earnings capability of the business was driven by the return to growth in revenues from continuing operations plus the on-going effects of the expense reductions that were implemented from late calendar 2005 through 2006 and into calendar 2007.

The improved profitability occurred despite the on-going depreciation of the value of the US dollar relative to the Australian dollar, which adversely affected reported revenues by approximately \$2.0m, and earnings in the current half-year by approximately \$0.4m.

Whilst significant work has been done to bring the business back to profitability, and now improving profitability, much work still remains to be done to achieve satisfactory earnings from a market perspective. To this end, the Company will continue to reduce expenses where it can and to logically continue to grow revenues from continuing operations by expanding market share in the US, Europe and Asia as well as selling into markets around the world where the Company currently does not have a presence, or has a small presence relative to the market opportunity.

Explanation of Dividends *(Appendix 4D item 2.6)*

No dividends were declared or paid in the period.

Compumedics Limited
Half-year report - 31 December 2007

Contents	Page
Directors' Report	5
Auditor's independence declaration	8
Interim financial report	
Consolidated income statement	9
Consolidated balance sheet	10
Consolidated statement of changes in equity	11
Consolidated cash flow statement	12
Notes to the financial statements for the half-year ended 31 December 2007	13
Directors' declaration	18
Independent auditor's review report to the members of Compumedics Limited	19
Supplementary Appendix 4D information	21

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2007 and any public announcements made by Compumedics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

Directors' Report

Interim Report – 31 December 2007

Your directors present their report on the consolidated entity consisting of Compumedics Limited and the entities it controlled at the end of, or during the half-year ended 31 December 2007.

Directors

The following persons were directors of Compumedics Limited during the whole of the half-year and up to the date of this report.

Mr. D. Burton
Mr. A. Anderson
Prof. G. Mitchell

Review of Operations

A summary of consolidated revenues and results for the half-year is set out below:

	6 mths ended Dec 2007	6 mths ended Dec 2006
Operating revenue (A\$'000)	20,076	19,733
Profit before interest, and tax (A\$'000)	1,950	748
Profit for the half-year (A\$'000)	1,613	461
Profit per share (cents)	1.1	0.0

Comments on the operations are as follows:

Business / Product Group Performance

Revenues from continuing operations were 2% higher at \$20.1m for the half-year to 31 December 2007 compared to \$19.70m for the previous corresponding half-year. Whilst the underlying business continued to improve this has not been reflected in the headline revenue numbers in Australian dollars due to:

- 1 the business not being able to ship all the orders it took through to 31 December 2007. The business took orders of about \$21m for the half-year to 31 December 2007, which compared to total orders taken in the corresponding previous half-year of \$19.6m or a 7% increase despite the exchange rate effect. The business was unable to ship all of these orders by 31 December 2007, in part because of the restrictive funding arrangements placed on the business by its (now previous) bankers; and
- 2 the on-going depreciation of the US dollar relative to the Australian dollar. The average AUD/USD exchange rate for the six months to December 31, 2007 was approximately 87 cents compared to 76 cents for the corresponding previous half-year. Had the Australian dollar stayed at the 76 US cent exchange rate from the corresponding half-year reported revenues for the half-year to 31 December 2007 would have been closer to \$22m or some \$2m more than what has been reported.

Revenues from continuing operations in the global sleep business were static overall at \$8.6m for the half-year ended 31 December 2007 when compared to the previous corresponding half-year. This reflected strong sales growth out of all parts of the world offset by a weak US first half-year performance. The weaker sales in the US were not market related but business specific and steps have been taken to restore the business performance in the second-half of the current financial year in the US sleep market. The sales performance for the US business as a whole also was affected by the much stronger Australian dollar relative to the US dollar as already noted.

Revenues from continuing operations in the Brain Research (Neuroscan) business were 24% ahead of the corresponding half-year at \$5.9m despite the exchange-rate impact. This largely reflected the generation of new business in the half-year using existing products from both the Compumedics and Neuroscan businesses in brain function testing as part of clinical drug trials for pharmaceutical companies. The core Brain Research business in Asia and the US, not including this new pharmaceutical business, performed strongly whilst the Australian and European businesses declined compared to last year. The declines in these two geographic areas largely reflected the cyclical nature of grant funding for this business area.

Revenues from continuing operations for the DWL business were 23% less than for the previous corresponding half-year at \$2.7m compared to \$3.5m reflecting lower sales in the US and Australia and some vendor specific issues in Germany with the delivery of new product. DWL had orders on-hand that had they shipped would have seen the DWL business deliver growth for the half-year to 31 December 2007, compared to the previous corresponding half-year.

Events subsequent to reporting date

As has been previously advised, Compumedics has been negotiating new financing facilities for the Company. On 14 January 2008 Compumedics implemented its new financial arrangements with HSBC. The new facilities do not change materially the bank financial liabilities reported at the half-year ending 31 December 2007. The new facilities do, however, provide the Company with a more flexible funding arrangement for financing the on-going working capital needs of the business. The new facilities remain in place until 30 September 2008, when they will be reviewed.

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 8.

Rounding of amounts

The Company is of a kind referred to in Class Order 98/0100 issued by the Australian Securities & Investments Commission, relating to the "rounding off" of amounts in the directors' report and financial report. Amounts in the directors' report and financial report have been rounded off to the nearest thousand dollars in accordance with that Class Order.

This report is made in accordance with a resolution of the directors.



D. Burton
Executive Chairman

Melbourne
February 26, 2008

Auditor's Independence Declaration

As lead auditor for the review of Compumedics Limited for the half year ended 31 December 2007, I declare that to the best of my knowledge and belief, there have been:

- a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- b) no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Compumedics Limited and the entities it controlled during the period.



Lisa Harker
Partner
PricewaterhouseCoopers

Melbourne
26 January 2008

Compumedics Limited
Consolidated income statement
for the half-year ended 31 December 2007

	Half-year 2007 \$'000	Half-year 2006 \$'000
Revenue from continuing operations	20,076	19,733
Cost of sales	(7,459)	(7,474)
Administration	(2,469)	(2,463)
Sales & Marketing	(5,917)	(6,219)
Research & Development	(2,281)	(2,631)
Finance costs	(337)	(485)
Profit before income tax	1,613	461
Income tax expense	-	-
Profit for the half-year	1,613	461
Profit attributable to members of Compumedics Limited	1,613	461
Earnings per share for profit from continuing operations attributable to the ordinary equity holders of the company:	Cents	Cents
Basic earnings per share	1.1	0.0
Diluted earnings per share	1.1	0.0

The above consolidated income statement should be read in conjunction with the accompanying notes.

Compumedics Limited
Consolidated balance sheet
as at 31 December 2007

	31 Dec 2007 \$'000	30 June 2007 \$'000
ASSETS		
Current assets		
Cash and cash equivalents	221	363
Receivables	13,877	12,464
Inventories	4,809	4,991
Total current assets	18,907	17,818
Non current assets		
Property, plant and equipment	697	613
Intangible assets	1,072	820
Total non current assets	1,769	1,433
Total assets	20,676	19,251
LIABILITIES		
Current Liabilities		
Payables	6,800	7,091
Interest bearing liabilities	3,068	3,396
Current tax liabilities	73	73
Provisions	886	697
Other	1,156	1,059
Total current liabilities	11,983	12,318
Non current liabilities		
Interest bearing liabilities	65	7
Provisions	91	12
Total non current liabilities	156	19
Total liabilities	12,139	12,337
Net assets	8,537	6,914
EQUITY		
Contributed equity	29,492	29,492
Reserves	(773)	(783)
Retained earnings	(20,182)	(21,795)
Total equity	8,537	6,914

The above consolidated balance sheet should be read in conjunction with the accompanying notes.

Compumedics Limited
Consolidated statement of changes
in equity for the half-year
ended 31 December 2007

	Half-year 2007 \$'000	Half-year 2006 \$'000
Total equity at the beginning of the half-year	6,914	6,717
Exchange differences on translation of foreign operations	10	(239)
Net income/(losses) recognised directly in equity	10	(239)
Profit for the half-year	1,613	461
Total recognised income and expenses for year	1,623	222
 Transactions with equity holders in their capacity as equity holders:		
Value of conversion rights on issue of Redeemable Convertible Notes (RCN's)	-	337
Total equity at the end of the half-year	8,537	7,276

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Compumedics Limited
Consolidated cash flow statement
for the half-year ended 31 December 2007

	Half-year 2007 \$'000	Half-year 2006 \$'000
Cash flows from operating activities		
Receipts from customers (inclusive of goods and services tax)	17,817	19,732
Payments to suppliers and employees (inclusive of goods and services tax)	(16,825)	(19,149)
Receipts from other income	234	-
Interest received	3	74
Interest and other costs of finance paid	(260)	(264)
Net cash inflow from operating activities	969	393
Cash flows from investing activities		
Payments for property, plant and equipment	(330)	-
Payments for intangible assets	(334)	-
Net cash (outflow) from investing activities	(664)	-
Cash flows from financing activities		
Proceeds from borrowings	-	-
Repayments of finance leases	(28)	(66)
Repayment of borrowings	(375)	(489)
Net cash (outflow) from financing activities	(403)	(555)
Net (decrease) in cash and cash equivalents	(98)	(162)
Cash and cash equivalents at the beginning of the half-year	(555)	2,353
Effects of exchange rate changes on cash	(44)	31
Cash and cash equivalents at the end of the half-year	(697)	2,222
Add back DWL overdraft presented as current interest bearing liabilities in the consolidated balance sheet	918	767
Cash and cash equivalents as reported in the consolidated balance sheet	221	2,989

The above consolidated cash flow statement should be read in conjunction with the accompanying notes.

Compumedics Limited
Notes to the financial statements
for the half-year ended 31 December 2007

1 Basis of preparation of consolidated half-year financial report

The financial report for the interim half-year reporting period ended 31 December 2007 has been prepared in accordance with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2007 and any public announcements made by Compumedics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

Going Concern

During the half-year ended 31 December, 2007 the consolidated entity (Compumedics) generated an operating profit of \$1.6m and positive cash flows from operations of \$1.0m. In the prior half-year period Compumedics generated an operating profit of \$0.5m and positive cash flows from operations of \$0.4m.

As the consolidated entity previously indicated in the ASX Final Report at 30 June 2007 approximately \$4.0m in costs on an annualised basis have been removed from the business and these are now fully reflected in this result along with additional profits from the growth in sales as well as on-going cost reductions.

The consolidated entity has implemented new funding arrangements with HSBC from 14 January 2008, which the consolidated entity believes will provide it with sufficient funding facilities. These new funding arrangements are further discussed in Note 4, Events occurring after balance date.

The continuing viability of the consolidated entity requires:

- The consolidated entity to achieve its budget and comply with its bank covenants
- Improvement in the terms under which receivables are collected
- The intention of the RCNs holder not to convert the RCNs into cash in March 2008
- Re-financing of the funding arrangements with HSBC Australia in September 2008

The Directors believe the consolidated entity will be successful in the above activities and accordingly have prepared the financial report on the basis that the Company will realise its assets and settle its liabilities and commitments in the normal course of business and for at least the amounts stated in the financial report.

Compumedics Limited
Notes to the consolidated financial statements
for the half-year ended 31 December 2007

Note 2. Segment information

Primary reporting format – business segments
Half-year 2007

	Sleep	Neuroscan (Brain Research)	Neuroscience (Clinical EEG + DWL)	Supplies	Intersegment Elimination	\$'000 Group
Total segment revenue	8,601	5,904	3,295	2,042	-	19,842
Unallocated revenue						234
Total revenue and and other income						20,076
SEGMENT RESULT	944	1,312	(967)	571	-	1,860
Unallocated revenue less unallocated expenses						(247)
Profit before income tax						1,613

Compumedics Limited
Notes to the consolidated financial statements
for the half-year ended 31 December 2007

Note 2. Segment information

Primary reporting format– business segments
Half-year 2006

	Sleep	Neuroscan (Brain Research)	Neuroscience (Clinical EEG + DWL)	Supplies	Intersegment Elimination	\$'000 Group
Total segment revenue	8,504	4,767	4,386	2,065	-	19,722
Unallocated revenue						11
Total revenue and other income						19,733
SEGMENT RESULT	1,074	(335)	(616)	708	-	831
Unallocated revenue less unallocated expenses						(370)
Profit before income tax						461

Compumedics Limited
Notes to the consolidated financial statements
for the half-year ended 31 December 2007

Note 3. Equity securities issued

On 16 March 2006 the Company issued Redeemable Convertible Notes (RCNs) to D&DJ Burton Holdings Pty Ltd (“Holder”) to the value of \$1 million which has been classified as debt.

The terms of this RCNs issue are:

1. The RCNs carry a coupon rate of interest of 20%pa as approved by shareholders at the annual general meeting of the company on 28 November 2006.
2. The RCNs are convertible into ordinary issued shares of the Company on the 1st and 2nd anniversaries of their issue.
3. The RCNs have a 2-year life.
4. The conversion factor to be used if the Holder elects to turn the RCNs into ordinary shares of the Company is the average share price for 5 days immediately prior to the issue of the RCNs. This has subsequently been calculated at 8.2 cents per share.
5. The \$1m was payable within 30 days of the issue of the RCNs.
6. The ability of the Holder to convert the RCNs into ordinary shares of the Company required the approval of the shareholders. The approval of the shareholders was obtained at the Annual General Meeting on 28 November 2006.

On 28 November 2006 at the annual general meeting of Compumedics Limited the shareholders approved the rights of the note holder to convert the RCNs to ordinary shares in Compumedics Limited as laid out in the terms of the RCNs document.

The shareholders at the same meeting also confirmed the interest rate of 20% pa which was a direct outcome to the shareholders approval of convertibility of the RCNs to ordinary shares in Compumedics Limited.

As a consequence the Holder is entitled to a coupon interest rate of 20% and may in the 7 day period up to 16 March 2008 convert or redeem some or all of the RCNs. However on 16 March 16 2008 the Company must redeem any outstanding RCNs at face value that point in time.

In addition the RCNs provide for interest to be paid annually on 16 March 2007 and 2008. The interest payable at that time can only be paid in ordinary shares pursuant to the terms of the RCNs.

The fair value of the RCNs is presented in the balance sheet as current interest bearing liabilities. The fair value of the conversion rights are presented in equity.

Compumedics Limited
Notes to the consolidated financial statements
for the half-year ended 31 December 2007

Note 4. Events occurring after balance date

As has been previously advised the Company has been negotiating new financing facilities. On 14 January 2008 the Company implemented its new financial arrangements with HSBC Australia. The new facilities do not change materially the bank financial liabilities reported in the half-year numbers at 31 December 2007. The new facilities do, however, provide the Company with a more flexible funding arrangement for financing the on-going working capital needs of the business. The new facilities remain in place until 30 September 2008, when they will be reviewed.

**Compumedics Limited
Directors' Declaration
for the half-year ended 31 December 2007**

In the directors' opinion:

(a) the financial statements and notes set out on pages 8 to 16 are in accordance with the *Corporations Act 2001*, including:

(i) complying with Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements; and

(ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2007 and of its performance, as represented by the results of its operations, changes in equity and its cash flows, for the half-year ended on that date; and

(b) there are reasonable grounds to believe that Compumedics Limited will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



David Burton
Executive Chairman

Melbourne
26 February 2008

**INDEPENDENT AUDITOR'S REVIEW REPORT
to the members of Compumedics Limited**

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Compumedics Limited, which comprises the balance sheet as at 31 December 2007, and the income statement, statement of changes in equity and cash flow statement for the half-year ended on that date, other selected explanatory notes and the directors' declaration for the Compumedics Limited Group (the consolidated entity). The consolidated entity comprises both Compumedics Limited (the company) and the entities it controlled during that half-year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation and fair presentation of the half-year financial report in accordance with Australian Accounting Standards (including the Australian Accounting Interpretations) and the *Corporations Act 2001*. This responsibility includes establishing and maintaining internal control relevant to the preparation and fair presentation of the half-year financial report that is free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of an Interim Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2007 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Compumedics Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. It also includes reading the other information included with the financial report to determine whether it contains any material inconsistencies with the financial report. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

For further explanation of a review, visit our website www.pwc.com/au/financialstatementaudit.

While we considered the effectiveness of management's internal controls over financial reporting when determining the nature and extent of our procedures, our review was not designed to provide assurance on internal controls.

Our review did not involve an analysis of the prudence of business decisions made by directors or management.

Matters relating to the electronic presentation of the reviewed financial report

This review report relates to the financial report of Compumedics Limited (the company) for the half-year ended 31 December 2007 included on Compumedics Limited's web site. The company's directors are responsible for the integrity of the Compumedics Limited web site. We have not been engaged to report on the integrity of this web site. The review report refers only to the financial report identified above. It does not provide an opinion on any other information which may have been hyperlinked to/from the financial report. If users of this report are concerned with the inherent risks arising from electronic data communications they are advised to refer to the hard copy of the reviewed financial report to confirm the information included in the reviewed financial report presented on this web site.


Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Compumedics Limited is not in accordance with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2007 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting and Corporations Regulations 2001*.



PricewaterhouseCoopers



Lisa Harker
Partner

Melbourne
26 February 2008

Compumedics Limited
Supplementary Appendix 4D information
for the half-year ended 31 December 2007

NTA Backing *(Appendix 4D item 3)*

	2007	2006
Net tangible asset backing per ordinary share	5.3cents	5.2 cents

Additional dividend/distribution information ² *(Appendix 4D item 5)*

Details of dividends/distributions declared or paid during or subsequent to the year ended 31 December 2006 are as follows:

Record date	Payment date	Type	Amount per security	Total dividend	Franked amount per security	Foreign sourced dividend amount per security
N/A	N/A	N/A	N/A	N/A	N/A	N/A

Dividend/distribution reinvestment plans *(Appendix 4D item 6)*

NOT APPLICABLE

Compumedics Limited
Supplementary Appendix 4D information
for the half-year ended 31 December 2007

Material factors affecting the revenues and expenses of the economic entity for the current period

The major impacts to the revenues and expenses of the economic entity in the half-year to 31 December 2007 have already been disclosed elsewhere in this document.

Material factors affecting the assets, liabilities and equity of the economic entity for the current period

The major factors impacting the assets and liabilities of the Company relate to the on-going turn around of the Company following its restructure and as evidenced by these results.

Material factors affecting the cash flows of the economic entity for the current period

The major factors impacting the cash flows of the Company relate to the on-going turn around of the Company following its restructure and as evidenced by these results.